213 related articles for article (PubMed ID: 20544193)
41. (18)F-Choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer.
Kwee SA; Coel MN; Ly BH; Lim J
Ann Nucl Med; 2009 Aug; 23(6):541-8. PubMed ID: 19529978
[TBL] [Abstract][Full Text] [Related]
42. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
[TBL] [Abstract][Full Text] [Related]
43. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
44. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
[TBL] [Abstract][Full Text] [Related]
45. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
46. ¹⁸F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility.
Gómez-Río M; Testart Dardel N; Santiago Chinchilla A; Rodríguez-Fernández A; Olivares Granados G; Luque Caro R; Zurita Herrera M; Chamorro Santos CE; Lardelli-Claret P; Llamas-Elvira JM
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):886-95. PubMed ID: 25673054
[TBL] [Abstract][Full Text] [Related]
47. Brain metastases in patient with prostate cancer found in 18F-choline PET/CT.
Gizewska A; Witkowska-Patena E; Stembrowicz-Nowakowska Z; Buraczewska A; Dziuk M
Nucl Med Rev Cent East Eur; 2015; 18(1):39-41. PubMed ID: 25633517
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging.
Nitsch S; Hakenberg OW; Heuschkel M; Dräger D; Hildebrandt G; Krause BJ; Schwarzenböck SM
J Nucl Med; 2016 Oct; 57(Suppl 3):38S-42S. PubMed ID: 27694169
[TBL] [Abstract][Full Text] [Related]
50. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
51. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
Chalaye J; Costentin CE; Luciani A; Amaddeo G; Ganne-Carrié N; Baranes L; Allaire M; Calderaro J; Azoulay D; Nahon P; Seror O; Mallat A; Soussan M; Duvoux C; Itti E; Nault JC
J Hepatol; 2018 Aug; 69(2):336-344. PubMed ID: 29518452
[TBL] [Abstract][Full Text] [Related]
52. Usefulness of
López Rodríguez E; Tirado Hospital JL; Álvarez Pérez RM; Gómez Izquierdo L; Jiménez-Hoyuela JM
Actas Urol Esp (Engl Ed); 2020; 44(6):437-443. PubMed ID: 32576406
[TBL] [Abstract][Full Text] [Related]
53.
Kanoun S; Walker P; Vrigneaud JM; Depardon E; Barbier V; Humbert O; Moulin M; Créhange G; Cormier L; Loffroy R; Brunotte F; Cochet A
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):986-994. PubMed ID: 28333020
[TBL] [Abstract][Full Text] [Related]
54. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
[TBL] [Abstract][Full Text] [Related]
55. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.
Talbot JN; Gutman F; Fartoux L; Grange JD; Ganne N; Kerrou K; Grahek D; Montravers F; Poupon R; Rosmorduc O
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1285-9. PubMed ID: 16802155
[TBL] [Abstract][Full Text] [Related]
56. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2010; 12(1):98-107. PubMed ID: 19588206
[TBL] [Abstract][Full Text] [Related]
57. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
58. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
59. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.
Rietbergen DD; van der Hiel B; Vogel W; Stokkel MP
Nucl Med Commun; 2011 Dec; 32(12):1143-7. PubMed ID: 22045476
[TBL] [Abstract][Full Text] [Related]
60.
Ferda J; Ferdová E; Baxa J; Fínek J; Topolčan O
Anticancer Res; 2018 Jul; 38(7):4139-4143. PubMed ID: 29970541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
